Suppr超能文献

24 小时血压和心率对左心室射血分数降低和中值的患者预后的影响。

Effect of 24-hour blood pressure and heart rate on the prognosis of patients with reduced and midrange LVEF.

机构信息

Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia Faculty of Fundamental Medicine, Lomonosov Moscow State University, Russia.

Academician Chapidze Center for Emergency Cardiology, Tbilisi, Georgia.

出版信息

Kardiologiia. 2021 Jul 31;61(7):4-13. doi: 10.18087/cardio.2021.7.n1684.

Abstract

Aim    Optimal combination therapy for chronic heart failure (CHF) currently implies the mandatory use of at least four classes of drugs: renin-angiotensin-aldosterone (RAAS) system inhibitors or angiotensin receptor blocker neprilysin inhibitors (ARNI); beta-adrenoblockers (BAB); mineralocorticoid receptor antagonists; and sodium-glucose cotransporter 2 inhibitors. Furthermore, many of these drugs are able to decrease blood pressure even to hypotension and alleviate tachycardia. This study focused on the relationship of 24-h blood pressure (BP) and heart rate (HR) with the prognosis for CHF patients with sinus rhythm and left ventricular ejection fraction (LV EF) <50 % as well as on suggesting possible variants of safe therapy for CHF depending on the combination of studied factors.Material and methods    Effects of clinical data, echocardiographic parameters, 24-h BP, and heart rhythm (data from 24-h BP and ECG monitors) on the prognosis of 155 patients with clinically pronounced CHF, LV EF <50 %, and sinus rhythm who were followed up for 5 years after discharge from the hospital.Results    The one-factor analysis showed that the prognosis of CHF patients was statistically significantly influenced by the more severe functional class (FC) III CHF compared to FC II, reduced LV EF (<35 %), a lower 24-h systolic BP (SBP) (<103 mm Hg), the absence of hypotensive episodes in daytime, a low variability of nighttime BP (<7.5 mm Hg), a higher 24-h HR (>71 bpm vs. <60 bpm), the absence of therapy with RAAS inhibitors + BAB, and a lower body weight index. The multi-factor analysis showed that more severe CHF FC, lower LV EF, and the absence of RAAS inhibitors + BAB therapy retained the influence on the prognosis. After eliminating the influencing factor of drug therapy, also a low SBP variability significantly influenced the prognosis. An additional analysis determined the following four groups of CHF patients with reduced heart systolic function according to mean 24-h HR and SBP: the largest group (38.1 % of all patients) with controlled HR (≤69 bpm), preserved SBP (>103 mm Hg), and the lowest death rate of 15.3 %; the group with increased HR (>69 bpm) but preserved SBP (30.3 % of all patients) where the death rate was 44.7 %, which was significantly higher than in the first group; the group with normal HR (≤69 bpm) but reduced SBP (≤103 mm Hg) (16.1 % of patients) where the death rate was 40 %, which was comparable with the second group and significantly worse than in the first group; and the group with both increased HR (>69 bpm) and reduced SBP (≤103 mm Hg) (15.5 % of patients), which resulted in the maximal risk of death (70.8 % of patients with CHF and LV EF <50 %), which was significantly higher than in the three other groups.Conclusion    Low SBP (including 24-h SBP with reduced variability in day- and nighttime) in combination with high HR (including by data of Holter monitoring), low LV EF, more severe clinical course of CHF, and the absence of an adequate treatment with neurohormonal modulators (RAAS inhibitors and BAB) significantly increased the risk of death. Isolating four types of FC II-III CHF with sinus rhythm and EF <50% based on the combination of HR and BP identifies patients with an unfavorable prognosis, which will help developing differentiated therapeutic approaches taking into account clinical features.

摘要

目的

慢性心力衰竭(CHF)的最佳联合治疗目前意味着必须至少使用四类药物:肾素-血管紧张素-醛固酮(RAAS)系统抑制剂或血管紧张素受体脑啡肽酶抑制剂(ARNI);β-肾上腺素能阻滞剂(BAB);盐皮质激素受体拮抗剂;以及钠-葡萄糖共转运蛋白 2 抑制剂。此外,许多这些药物能够降低血压,甚至降低至低血压,并缓解心动过速。本研究侧重于 24 小时血压(BP)和心率(HR)与窦性节律和左心室射血分数(LV EF)<50%的 CHF 患者预后的关系,以及根据研究因素的组合,为 CHF 提出可能的安全治疗方案。

材料和方法

对 155 例临床显著 CHF、LV EF <50%和窦性节律患者的临床数据、超声心动图参数、24 小时 BP 和心律(24 小时 BP 和心电图监测数据)对预后的影响进行了分析。这些患者在出院后随访了 5 年。

结果

单因素分析显示,CHF 患者的预后受到更严重的功能分级(FC)III CHF 的统计学显著影响,与 FC II 相比,LV EF 降低(<35%),24 小时收缩压(SBP)较低(<103mmHg),白天无低血压发作,夜间 BP 变异性较低(<7.5mmHg),24 小时 HR 较高(>71bpm 与 <60bpm),未接受 RAAS 抑制剂+BAB 治疗,体重指数较低。多因素分析显示,更严重的 CHF FC、更低的 LV EF 和缺乏 RAAS 抑制剂+BAB 治疗仍然对预后有影响。在消除药物治疗的影响因素后,SBP 变异性较低也显著影响预后。进一步的分析根据平均 24 小时 HR 和 SBP 确定了具有降低心脏收缩功能的四个 CHF 患者组:最大组(所有患者的 38.1%)具有控制的 HR(≤69bpm)、保留的 SBP(>103mmHg)和最低的死亡率为 15.3%;HR 升高(>69bpm)但 SBP 保留(所有患者的 30.3%)的组死亡率为 44.7%,明显高于第一组;HR 正常(≤69bpm)但 SBP 降低(≤103mmHg)(16.1%的患者)的组死亡率为 40%,与第二组相当,但明显高于第一组;以及 HR 升高(>69bpm)和 SBP 降低(≤103mmHg)的组(所有患者的 15.5%),导致死亡风险最高(LV EF <50%的 CHF 患者为 70.8%),明显高于其他三组。

结论

低 SBP(包括昼夜 SBP 变异性降低)与高 HR(包括动态心电图监测数据)、低 LV EF、更严重的 CHF 临床过程以及神经激素调节剂(RAAS 抑制剂和 BAB)治疗不足相结合,显著增加了死亡风险。基于 HR 和 BP 的组合,将窦性节律和 EF <50%的 FC II-III CHF 分为四种类型,可以识别预后不良的患者,这将有助于制定考虑临床特征的差异化治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验